BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 32083759)

  • 1. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice.
    Rajas F; Dentin R; Cannella Miliano A; Silva M; Raffin M; Levavasseur F; Gautier-Stein A; Postic C; Mithieux G
    Mol Metab; 2021 Jan; 43():101108. PubMed ID: 33137488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic ChREBP orchestrates intrahepatic carbohydrate metabolism to limit hepatic glucose 6-phosphate and glycogen accumulation in a mouse model for acute Glycogen Storage Disease type Ib.
    Krishnamurthy KA; Rutten MGS; Hoogerland JA; van Dijk TH; Bos T; Koehorst M; de Vries MP; Kloosterhuis NJ; Havinga H; Schomakers BV; van Weeghel M; Wolters JC; Bakker BM; Oosterveer MH
    Mol Metab; 2024 Jan; 79():101838. PubMed ID: 37995884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
    Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
    J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia.
    Rutten MGS; Lei Y; Hoogerland JH; Bloks VW; Yang H; Bos T; Krishnamurthy KA; Bleeker A; Koster MH; Thomas RE; Wolters JC; van den Bos H; Mithieux G; Rajas F; Mardinoglu A; Spierings DCJ; de Bruin A; van de Sluis B; Oosterveer MH
    Cancer Metab; 2023 Apr; 11(1):5. PubMed ID: 37085901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.
    Rutten MGS; Derks TGJ; Huijkman NCA; Bos T; Kloosterhuis NJ; van de Kolk KCWA; Wolters JC; Koster MH; Bongiovanni L; Thomas RE; de Bruin A; van de Sluis B; Oosterveer MH
    Hepatology; 2021 Nov; 74(5):2491-2507. PubMed ID: 34157136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.
    Grefhorst A; Schreurs M; Oosterveer MH; Cortés VA; Havinga R; Herling AW; Reijngoud DJ; Groen AK; Kuipers F
    Biochem J; 2010 Dec; 432(2):249-54. PubMed ID: 20854262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
    Fisher FM; Kim M; Doridot L; Cunniff JC; Parker TS; Levine DM; Hellerstein MK; Hudgins LC; Maratos-Flier E; Herman MA
    Mol Metab; 2017 Jan; 6(1):14-21. PubMed ID: 28123933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
    Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
    Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
    [No Abstract]   [Full Text] [Related]  

  • 10. ChREBP Rather Than SHP Regulates Hepatic VLDL Secretion.
    Niwa H; Iizuka K; Kato T; Wu W; Tsuchida H; Takao K; Horikawa Y; Takeda J
    Nutrients; 2018 Mar; 10(3):. PubMed ID: 29518948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-β and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.
    Shimada M; Ichigo Y; Shirouchi B; Takashima S; Inagaki M; Nakagawa T; Hayakawa T
    Nutr Res; 2019 Apr; 64():49-55. PubMed ID: 30802722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ChREBP regulates fructose-induced glucose production independently of insulin signaling.
    Kim MS; Krawczyk SA; Doridot L; Fowler AJ; Wang JX; Trauger SA; Noh HL; Kang HJ; Meissen JK; Blatnik M; Kim JK; Lai M; Herman MA
    J Clin Invest; 2016 Nov; 126(11):4372-4386. PubMed ID: 27669460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.
    Yang M; Liu Q; Huang T; Tan W; Qu L; Chen T; Pan H; Chen L; Liu J; Wong CW; Lu WW; Guan M
    Theranostics; 2020; 10(24):10874-10891. PubMed ID: 33042259
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mediator complex kinase module is necessary for fructose regulation of liver glycogen levels through induction of glucose-6-phosphatase catalytic subunit (G6pc).
    Youn DY; Xiaoli AM; Zong H; Okada J; Liu L; Pessin J; Pessin JE; Yang F
    Mol Metab; 2021 Jun; 48():101227. PubMed ID: 33812059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F6P/G6P-mediated ChREBP activation promotes the insulin resistance-driven hepatic lipid deposition in zebrafish.
    Gong Y; Lu Q; Xi L; Liu Y; Yang B; Su J; Liu H; Jin J; Zhang Z; Yang Y; Zhu X; Xie S; Han D
    J Nutr Biochem; 2023 Dec; 122():109452. PubMed ID: 37748621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
    Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
    J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonally Induced Hepatocellular Carcinoma in Diabetic Wild Type and Carbohydrate Responsive Element Binding Protein Knockout Mice.
    Nuernberger V; Mortoga S; Metzendorf C; Burkert C; Ehricke K; Knuth E; Zimmer J; Singer S; Nath N; Karim M; Yasser M; Calvisi DF; Dombrowski F; Ribback S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.